- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04781140
Evaluación de SPN-812 (cápsula de liberación prolongada de viloxazina) en niños en edad preescolar con TDAH
Estudio de fase 4, aleatorizado, doble ciego, multicéntrico, controlado con placebo, de grupos paralelos sobre la eficacia y seguridad de SPN-812 en niños en edad preescolar (4 a 5 años) con trastorno por déficit de atención/hiperactividad (TDAH) )
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel-group, efficacy and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with ADHD. Participants will be screened for eligibility for up to 4 weeks. Eligible participants will be treated with study medication for 6 weeks. The total duration of the study is up to 10 weeks.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Olivia Elbaum
- Número de teléfono: 301-838-2500
- Correo electrónico: clinicaltrials@supernus.com
Ubicaciones de estudio
-
-
Alabama
-
Saraland, Alabama, Estados Unidos, 36571
- Reclutamiento
- The Center for Clinical Trials, Inc.
-
Contacto:
- Número de teléfono: 251-341-7021
- Correo electrónico: info@thecenterforclinicaltrials.com
-
-
Arkansas
-
Fayetteville, Arkansas, Estados Unidos, 72703
- Retirado
- Preferred Research Partners-NWA, LLC
-
Little Rock, Arkansas, Estados Unidos, 72211
- Reclutamiento
- Preferred Research Partners, Inc.
-
Contacto:
- Número de teléfono: 501-553-9987
- Correo electrónico: info@preferredresearchpartners.com
-
-
California
-
Anaheim, California, Estados Unidos, 92805
- Reclutamiento
- Advanced Research Center (ARC), Inc.
-
Contacto:
- Número de teléfono: 714-999-6688
- Correo electrónico: contact@arctrials.com
-
Encino, California, Estados Unidos, 91316
- Retirado
- Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Encino]
-
Garden Grove, California, Estados Unidos, 92844
- Terminado
- National Institute of Clinical Research (PICR)
-
Imperial, California, Estados Unidos, 92251
- Reclutamiento
- Sun Valley Research Center
-
Contacto:
- Número de teléfono: 760-545-0123
- Correo electrónico: svrcinfo@sunvalleyb.com
-
Long Beach, California, Estados Unidos, 90807
- Reclutamiento
- Alliance Research
-
Contacto:
- Número de teléfono: 562-548-8500
- Correo electrónico: Research@asclepes.com
-
Newport Beach, California, Estados Unidos, 92660
- Retirado
- Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Newport Beach]
-
-
Colorado
-
Centennial, Colorado, Estados Unidos, 80112
- Reclutamiento
- IMMUNOe Research Centers
-
Contacto:
- Número de teléfono: 303-771-9000
- Correo electrónico: verosinfo@veroshealth.com
-
Contacto:
- Número de teléfono: 303-773-9000
-
-
Florida
-
Clermont, Florida, Estados Unidos, 34711
- Retirado
- Vertex Clinical Research, LLC
-
Coral Gables, Florida, Estados Unidos, 33134
- Reclutamiento
- Luna Research Center
-
Contacto:
- Número de teléfono: 305-613-7761
-
Gainesville, Florida, Estados Unidos, 32607
- Terminado
- Sarkis Clinical Trials
-
Jacksonville, Florida, Estados Unidos, 32256
- Reclutamiento
- Clinical Neuroscience Solutions, Inc.
-
Contacto:
- Número de teléfono: 904-281-5757
-
Lakeland, Florida, Estados Unidos, 33803
- Terminado
- Accel Research Sites - Lakeland CRU
-
Miami, Florida, Estados Unidos, 33155
- Reclutamiento
- Avantis Clinical Research LLC
-
Contacto:
- Número de teléfono: 305-515-9006
- Correo electrónico: info@avantisclinicalresearch.com
-
Orange City, Florida, Estados Unidos, 32763
- Reclutamiento
- Medical Research Group of Central Florida
-
Contacto:
- Número de teléfono: 386-775-7627
-
Orlando, Florida, Estados Unidos, 32801
- Reclutamiento
- Clinical Neuroscience Solutions, Inc.
-
Contacto:
- Número de teléfono: 407-425-5100
- Correo electrónico: orlinfo@cnshealthcare.com
-
Orlando, Florida, Estados Unidos, 32803
- Reclutamiento
- APG Research LLC
-
Contacto:
- Número de teléfono: 166 407-423-7149
- Correo electrónico: kkenworthyapg@gmail.com
-
Contacto:
- Número de teléfono: 165 407-423-7149
-
Tamarac, Florida, Estados Unidos, 33321
- Reclutamiento
- D&H Tamarac Research Center
-
Contacto:
- Número de teléfono: 786-375-6210
- Correo electrónico: info@dhnrc.com
-
Virginia Gardens, Florida, Estados Unidos, 33166
- Reclutamiento
- Hope Research Network, LLC.
-
Contacto:
- Número de teléfono: 786-953-8858
- Correo electrónico: info@hoperesearchnetwork.com
-
Winter Park, Florida, Estados Unidos, 32789
- Reclutamiento
- Pediatric Neurology and Epilepsy Specialists
-
Contacto:
- Número de teléfono: 121 407-293-1122
- Correo electrónico: ARiveraDelValle@pediatricneurologyandepilepsy.com
-
Contacto:
- Número de teléfono: 126 407-293-1122
- Correo electrónico: DHubert@pediatricneurologyandepilepsy.com
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30328
- Reclutamiento
- Clinical Integrative Research Center of Atlanta
-
Contacto:
- Número de teléfono: 678-705-7341
-
Atlanta, Georgia, Estados Unidos, 30318
- Reclutamiento
- Advanced Discovery Research LLC
-
Contacto:
- Número de teléfono: 470-777-8839
- Correo electrónico: contact@advdiscovery.com
-
Decatur, Georgia, Estados Unidos, 30030
- Reclutamiento
- CenExcel iResearch, LLC
-
Contacto:
- Número de teléfono: 404-537-1281
-
Savannah, Georgia, Estados Unidos, 31405
- Reclutamiento
- CenExel iResearch, LLC.
-
Contacto:
- Número de teléfono: 912-744-0800
-
-
Indiana
-
Evansville, Indiana, Estados Unidos, 47715
- Terminado
- Qualmedica Research, LLC.
-
-
Kentucky
-
Bardstown, Kentucky, Estados Unidos, 40004
- Reclutamiento
- Kentucky Pediatric/Adult Research
-
Contacto:
- Número de teléfono: 502-349-1569
- Correo electrónico: kpar@kpar.us
-
Owensboro, Kentucky, Estados Unidos, 42301
- Terminado
- Qualmedica Research, LLC.
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70115
- Terminado
- DelRicht Research (Touro Medical Center)
-
Prairieville, Louisiana, Estados Unidos, 70769
- Reclutamiento
- DelRicht Research
-
Contacto:
- Número de teléfono: 225-412-0316
- Correo electrónico: info@delricht.com
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21205
- Reclutamiento
- Kennedy Krieger Institute
-
Contacto:
- Número de teléfono: 443-923-3850
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02445
- Reclutamiento
- Boston Children's Hospital
-
Contacto:
- Número de teléfono: 617-919-6954
-
Contacto:
- Número de teléfono: 617-355-1118
- Correo electrónico: benamin.mills@childrens.harvard.edu
-
-
Michigan
-
Bloomfield Hills, Michigan, Estados Unidos, 48302
- Reclutamiento
- Neurobehavioral Medicine Group
-
Contacto:
- Número de teléfono: 248-290-5400
- Correo electrónico: info@neurobmg.com
-
-
Mississippi
-
Flowood, Mississippi, Estados Unidos, 39232
- Reclutamiento
- Precise Research Centers
-
Contacto:
- Número de teléfono: 601-420-5812
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89128
- Reclutamiento
- Clinical Research of Southern Nevada, LLC.
-
Contacto:
- Número de teléfono: 702-750-0000
- Correo electrónico: kluna.cpbm@gmail.com
-
-
New Jersey
-
Berlin, New Jersey, Estados Unidos, 08009
- Retirado
- Hassman Research Institute
-
Irvington, New Jersey, Estados Unidos, 07111
- Reclutamiento
- Med Clinical Research
-
Contacto:
- Número de teléfono: 908-798-8373
- Correo electrónico: info@medclinicalresearch.com
-
Neptune City, New Jersey, Estados Unidos, 07753
- Reclutamiento
- Jersey Shore University Medical Center
-
Contacto:
- Número de teléfono: 732-897-3640
- Correo electrónico: andrew.layman@hmhn.org
-
-
New York
-
New York, New York, Estados Unidos, 10028
- Retirado
- Icahn School of Medicine at Mount Sinai
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705
- Reclutamiento
- Duke University
-
Contacto:
- Número de teléfono: 919-681-1100
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Reclutamiento
- Cincinnati Children's Hospital and Medical Center
-
Contacto:
- Número de teléfono: 513-636-9763
- Correo electrónico: ADHDResearch@cchmc.org
-
West Chester, Ohio, Estados Unidos, 45069
- Retirado
- CincyScience
-
-
Oregon
-
Gresham, Oregon, Estados Unidos, 97030
- Reclutamiento
- Cyn3rgy Research
-
Contacto:
- Número de teléfono: 503-907-2179
- Correo electrónico: support@cyn3rgy.com
-
-
Pennsylvania
-
Hershey, Pennsylvania, Estados Unidos, 17033
- Reclutamiento
- Penn State Health Medical Group - Psychiatry and Behavioral Health
-
Contacto:
- Número de teléfono: 287364 717-531-0003
- Correo electrónico: rmyers12@pennstatehealth.psu.edu
-
Contacto:
- Número de teléfono: 717-531-5656
-
-
South Carolina
-
North Charleston, South Carolina, Estados Unidos, 29405
- Reclutamiento
- Coastal Carolina Research Center
-
Contacto:
- Número de teléfono: 843-856-3784
- Correo electrónico: CCRC@CoastalCarolinaResearch.com
-
Summerville, South Carolina, Estados Unidos, 29486
- Reclutamiento
- Coastal Pediatric Research
-
Contacto:
- Número de teléfono: 843-870-2225
- Correo electrónico: info.research@cpakids.com
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38119
- Reclutamiento
- Clinical Neuroscience Solutions, Inc.
-
Contacto:
- Número de teléfono: 901-843-1045
-
-
Texas
-
Bellaire, Texas, Estados Unidos, 77401
- Retirado
- Houston Clinical Trials, LLC.
-
Dallas, Texas, Estados Unidos, 75230
- Terminado
- Javara
-
Plano, Texas, Estados Unidos, 75093
- Reclutamiento
- AIM Trials, LLC
-
Contacto:
- Número de teléfono: 469-364-8804
- Correo electrónico: info@aimtrials.com
-
Contacto:
- Número de teléfono: 214-856-2778
-
The Woodlands, Texas, Estados Unidos, 77381
- Reclutamiento
- Family Psych of The Woodlands
-
Contacto:
- Número de teléfono: 281-367-1015
- Correo electrónico: info@woodlandspsych.com
-
-
Virginia
-
Petersburg, Virginia, Estados Unidos, 23805
- Reclutamiento
- Clinical Research Partners, LLC
-
Contacto:
- Número de teléfono: 804-921-9592
- Correo electrónico: Recruitment@ClinicalResearchRVA.com
-
Richmond, Virginia, Estados Unidos, 23220
- Reclutamiento
- Virginia Commonwealth University, Virginia Treatment Center for Children
-
Contacto:
- Número de teléfono: 804-628-8736
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Is male or female 4 years 0 months of age to less than or equal to 5 years 9 months of age at Visit 1 (Screening) and considered medically healthy.
- Subject's parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent before completing any study related procedures.
- Has a primary diagnosis of ADHD according to DSM-IV-TR criteria and confirmed with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL).
- Has an ADHD-RS-IV-P Total Score of ≥ 28 (males) or ≥ 24 (females) at Visit 1 (Screening) and at Visit 2 (Baseline).
- Has a CGI-S score of ≥ 4 (moderate or worse) at Visit 1 (Screening) and at Visit 2 (Baseline).
- Has undergone an adequate course of non-pharmacologic treatment or is having symptoms severe enough to warrant pharmacologic treatment without prior non-pharmacologic treatment.
- Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school, summer camp or childcare program) at least 2 days a week during study so as to assess symptoms and impairment in a setting outside the home.
- Has not initiated any behavioral intervention/therapy within 30 days of Visit 1 (Screening) and does not plan to initiate any new or discontinue any ongoing behavioral intervention/therapy during the study (e.g., subject is eligible if behavioral intervention/therapy is initiated 30 or more days prior to Visit 1 [Screening] and continues with a similar duration/frequency throughout their study).
- Subjects who are on ADHD medication at Visit 1 (Screening), but whose ADHD symptoms are not well controlled on current ADHD medication (e.g., meets Inclusion Criterion #4), meet all other inclusion/exclusion criteria, and discontinues ADHD medication at least 7 days prior to the day of Visit 2 (Baseline) are eligible to participate.
- Has no current condition in the opinion of the Investigator that could confound efficacy assessments, safety assessments or increase participant risk.
- Has lived with the same parent(s) or legal guardian(s) or has lived under a shared living arrangement (e.g., joint legal custody) for greater than or equal to 6 months prior to Visit 1 (Screening).
- Has a body weight ≥5th percentile for age and sex at Visit 1 (Screening) and Visit 2 (Baseline).
Exclusion Criteria:
- Has a diagnosis at Screening (per K-SADS-PL) of another psychiatric disorder that is considered to be the primary diagnosis rather than ADHD or has a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator (after consulting medical monitor), will likely interfere with study treatment adherence and/or impact study results.
- Has a current diagnosis of a major neurological disorder. The eligibility of those who have seizures, a history of seizure-like events (e.g., syncope, myoclonus, severe muscle spasms), a family history of seizure disorder (immediate family, i.e., sibling, parent), and/or febrile seizures will be assessed on a case-by-case basis after consulting the medical monitor.
- History of Bipolar Disorder diagnosed in a first degree relative.
- Has global development delay or intellectual disability by medical history.
- Has a current diagnosis of a significant (per Investigator's evaluation and/or judgement) systemic disease.
- Has body mass index > 95th percentile for the subject's age and sex at Visit 1 (Screening) or Visit 2 (Baseline).
- Has a mean resting systolic and diastolic blood pressure* that are both >95th percentile for age sex, and height and has a mean resting pulse rate* that is >95th percentile for age and sex (males: >117 bpm; females: >122 bpm) at Visit 1 (Screening) or Visit 2 (Baseline). * Note: The mean of three measurements while seated.
- Has a clinically significant electrocardiogram finding(s) at Visit 1 (Screening).
- Is currently taking SPN-812 for ADHD, has previously taken SPN-812 for ADHD, but discontinued due to a lack of efficacy or adverse reactions, or has history of allergic reaction, hypersensitivity or intolerance to viloxazine.
- Has an allergy to or cannot swallow pudding and applesauce and cannot swallow intact capsule whole.
- Has any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in the study.
- Has received any investigational drug within the longer of 30 days or 5 half-lives prior to Visit 2 (e.g., first dose of study medication).
- Has a positive urine drug test at Visit 1 (Screening). A positive test for amphetamines is allowed for subjects receiving a stimulant ADHD medication at Screening. The subject will be required to discontinue the stimulant for the duration of the study, beginning at least 7 days prior to Visit 2 (Baseline).
- Is using of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) during the Screening Period or (anticipated) for the duration of the study.
- Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
- Has suicidal ideation ("Yes" indicated on C-SSRS question 4 or 5) or suicidal behavior ("Yes" indicated on C-SSRS for any suicidal behavior) within 6 months prior to or the day of Visit 1 (Screening) or has attempted suicide ("Yes" indicated on C-SSRS for lifetime).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Placebo
Placebo, qd |
Placebo will be administered once daily |
|
Experimental: SPN-812
SPN-812, qd |
100mg SPN-812 will be administered once daily and compared to Placebo
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Total Score at End of Study (Week 6)
Periodo de tiempo: Baseline and Week 6
|
The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I", 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the ratings of all 18 items yields the raw Total score (range: 0-54; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline ADHD-RS-IV-P Total Score (<0) represents a better outcome. |
Baseline and Week 6
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score at End of Study (Week 6)
Periodo de tiempo: Baseline and Week 6
|
The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients (the higher the score, the more severe the overall ADHD symptoms). Post-baseline (raw) CGI-S scores are converted to a change from baseline score. A lower change from baseline CGI-S score (<0) represents a better outcome. |
Baseline and Week 6
|
|
Clinical Global Impression of Change (CGI-C) Score at End of Study (Week 6)
Periodo de tiempo: Week 6
|
The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". A CGI-C score <4 represents a better outcome. |
Week 6
|
|
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Hyperactivity/Impulsivity Subscale Score at End of Study (Week 6)
Periodo de tiempo: Baseline and Week 6
|
The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine H/I items yields the raw H/I subscale score (range: 0-27; the higher the H/I subscale score, the more severe the H/I symptoms). Post-baseline raw H/I subscale scores are converted to a change from baseline score. A lower change from baseline H/I subscale score (<0) represents a better outcome. |
Baseline and Week 6
|
|
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Inattention Subscale Score at End of Study (Week 6)
Periodo de tiempo: Baseline and Week 6
|
The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine IA items yields the raw IA subscale score (range: 0-27; the higher the IA subscale score, the more severe the IA symptoms). Post-baseline raw IA subscale scores are converted to a change from baseline score. A lower change from baseline IA subscale score (<0) represents a better outcome. |
Baseline and Week 6
|
|
Clinical Global Impression of Severity (CGI-S) Responder Rate (percentage of subjects with CGI-S score of 1 or 2) at End of Study (Week 6)
Periodo de tiempo: Baseline and Week 6
|
The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients. The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders". |
Baseline and Week 6
|
|
Clinical Global Impression of Change (CGI-C) Responder Rate (percentage of subjects with CGI-C score of 1 or 2) at End of Study (Week 6)
Periodo de tiempo: Week 6
|
The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders". |
Week 6
|
|
Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Responder Rate (percentage of subjects with ≥ 50% Reduction in Change from Baseline) at End of Study (Week 6)
Periodo de tiempo: Baseline and Week 6
|
The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two 9 item subscales: inattention and hyperactivity-impulsivity. The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale; 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. Sum of 18 ratings yields the Total score (range: 0-54; higher score represents severer symptoms). Percent reduction is calculated for the ADHD-RS-IV-P score: [("Post-baseline"-"Baseline")/"Baseline"] x 100; range: 0 to 100%; a "responder" is a subject with a 50% or greater reduction in change from baseline Total score. Responder rate (percent of responders) is calculated: ["number of 'responders' (m)"/ "number of subjects analyzed" (n)] X 100; range: 0 to 100%. A Responder Rate greater than 50%, represents more "responders" versus "nonresponders". |
Baseline and Week 6
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Joseph Hull, PhD, Supernus Pharmaceuticals, Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 812P401
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .